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Introduction {#jdi13012-sec-0005}
============

It is estimated that \>150 million people in the Western Pacific region have diabetes, with 7.2 million cases in Japan in 2015[1](#jdi13012-bib-0001){ref-type="ref"}. Compared with White patients, East Asian patients with type 2 diabetes mellitus generally have greater β‐cell dysfunction and reduced insulin secretory capacity, but less obesity and insulin resistance[2](#jdi13012-bib-0002){ref-type="ref"}. The 2016--2017 Japanese Diabetes Society Treatment Guide for Diabetes recommends that patients with decreased insulin secretory capacity should be treated with an insulin secretagogue, specifically a sulfonylurea, glinide or dipeptidyl peptidase‐4 (DPP‐4) inhibitor[3](#jdi13012-bib-0003){ref-type="ref"}. Analysis of Japanese health insurance claims database data showed that \>70% of patients with type 2 diabetes mellitus received DPP‐4 inhibitors[4](#jdi13012-bib-0004){ref-type="ref"}, [5](#jdi13012-bib-0005){ref-type="ref"}. Furthermore, 60% of patients initiating DPP‐4 inhibitors were drug‐naïve, showing the prevalent use of these drugs as first‐line treatments[4](#jdi13012-bib-0004){ref-type="ref"}, [5](#jdi13012-bib-0005){ref-type="ref"}. This preference can potentially be explained in part by the lower risk of hypoglycemia for DPP‐4 inhibitors compared with sulfonylureas or glinides[6](#jdi13012-bib-0006){ref-type="ref"}. The particular efficacy of DPP‐4 inhibitors in the Asian population was shown in a meta‐analysis of 55 randomized, controlled trials, with DPP‐4 inhibitors lowering glycated hemoglobin (HbA1c) to a greater extent in studies with ≥50% Asian participants compared with trials with \<50% Asian participants[7](#jdi13012-bib-0007){ref-type="ref"}.

The first DPP‐4 inhibitor was launched in Japan in 2009, and has since been followed by eight other drugs from this class, including linagliptin in 2011. Unlike many other glucose‐lowering drugs (GLDs), linagliptin can be administered in patients with renal or hepatic impairment without adjustment of the standard clinical dosage (5 mg once daily)[8](#jdi13012-bib-0008){ref-type="ref"}, [9](#jdi13012-bib-0009){ref-type="ref"}, [10](#jdi13012-bib-0010){ref-type="ref"}, [11](#jdi13012-bib-0011){ref-type="ref"}, [12](#jdi13012-bib-0012){ref-type="ref"}. Clinical trials have confirmed the efficacy of linagliptin in patients with kidney disease, liver disease and cardiovascular disease[13](#jdi13012-bib-0013){ref-type="ref"}, [14](#jdi13012-bib-0014){ref-type="ref"}, [15](#jdi13012-bib-0015){ref-type="ref"}, [16](#jdi13012-bib-0016){ref-type="ref"}, [17](#jdi13012-bib-0017){ref-type="ref"}, [18](#jdi13012-bib-0018){ref-type="ref"}. Consequently, in clinical practice, linagliptin might be chosen over other GLDs for patients with type 2 diabetes mellitus and concomitant renal or hepatic impairment. Such preferential prescribing or "channeling" was observed for linagliptin in a USA study of 1,174,476 type 2 diabetes mellitus patients initiating therapy within a commercial insurance dataset[19](#jdi13012-bib-0019){ref-type="ref"}. Equivalent data in the Japanese population are currently lacking.

In Japan, post‐approval execution of post‐marketing surveillance (PMS) is required by the Japanese Pharmaceutical Affairs Law in order to accumulate safety and effectiveness data for re‐examination. These studies have a pre‐specified design in accordance with Good Post‐marketing Surveillance Practice, as specified by the Ministry of Health, Labor and Welfare Ordinance No. 171 (20 December 2004).[20](#jdi13012-bib-0020){ref-type="ref"} At the time this PMS was carried out, data were usually requested from approximately 3,000 patients treated with a new DPP‐4 inhibitor over a re‐examination period of approximately 8 years. The primary aim of PMS studies is to examine drug safety in a wider population treated in daily practice compared with the phase III clinical trial population. Patients are eligible for inclusion according to the Japan package insert for the drug under study. Post‐marketing surveillance studies are observational and usually do not include patients treated with comparator drugs. As such, information from these surveillance studies might be challenging to put into context if no additional recent clinical practice data from the respective patient population already exists. Importantly, other studies in Japan have shown that differences among type 2 diabetes mellitus patient age, duration of diabetes, obesity and glycemic control at baseline influenced treatment choice[21](#jdi13012-bib-0021){ref-type="ref"}, and bodyweight and glycemic control differed among metformin, DPP‐4 inhibitors and sulfonylureas in accordance with differences in patient clinical features[22](#jdi13012-bib-0022){ref-type="ref"}. Furthermore, type 2 diabetes mellitus patients often have a significant burden of comorbid conditions, which might impact treatment choice. Studies carried out in the Japanese population have shown that many patients with type 2 diabetes mellitus have dyslipidemia, hypertension, chronic kidney disease (CKD) and cardiovascular/macrovascular disease[23](#jdi13012-bib-0023){ref-type="ref"}, [24](#jdi13012-bib-0024){ref-type="ref"}, [25](#jdi13012-bib-0025){ref-type="ref"}, [26](#jdi13012-bib-0026){ref-type="ref"}.

The expanded linagliptin PMS study (NCT01650259) is a prospective, observational study to evaluate the safety of linagliptin over a 36‐month treatment period based on the standard Japanese Pharmaceutical Affairs Law requirement. As linagliptin might be chosen over other GLDs for type 2 diabetes mellitus patients with concomitant renal or hepatic impairment in clinical practice, the standard PMS study design was expanded to collect baseline demographic and clinical data for patients starting GLDs other than linagliptin. The purpose of the analysis of the baseline data reported herein was to characterize GLD treatment patterns and identify any preferential prescribing that could influence interpretation of the standard PMS safety data.

Methods {#jdi13012-sec-0006}
=======

The linagliptin PMS study aimed to gather data from \>3,000 type 2 diabetes mellitus patients from hospitals and general clinics across Japan between 2012 and 2014 using a continuous investigation system[27](#jdi13012-bib-0027){ref-type="ref"}. For the expansion, sequential enrollment was applied: a patient beginning monotherapy treatment with linagliptin was enrolled, then the patient immediately following who was starting monotherapy with any GLD other than linagliptin (treatment‐naïve or switched from prior therapy with a different oral antidiabetic drug) was also enrolled. This sequential enrollment was then repeated. Monotherapy users of other GLDs were the chosen comparator in order to ensure that patients were at a similar stage of diabetes treatment. Patients were eligible for inclusion according to the linagliptin Japan package insert, with no further inclusion/exclusion criteria defined. As an observational study, no study medication was provided to the participants, and treatment decisions were solely at the discretion of the physician and the patient. In accordance with Japanese regulations for PMS studies, institutional review board review was not required, and written informed consent was not required from patients before their participation. However, institutional review boards located in the hospitals participating in this study approved our study before initiation.

In addition to the standard data collected to satisfy the requirements for the PMS, additional baseline characteristics were collected at study entry. These characteristics were analyzed based on the Medical Dictionary for Regulatory Activities (MedDRA^®^ version 16.0) system organ class (SOC) and preferred term (distinct descriptors for symptoms, signs, disease diagnoses, therapeutic indications, investigations, surgical or medical procedures and medical social or family history characteristics) for selected SOCs (Table [S1](#jdi13012-sup-0001){ref-type="supplementary-material"})[28](#jdi13012-bib-0028){ref-type="ref"}. Comparisons were made between patients initiating linagliptin versus patients initiating other GLDs, versus patients initiating other drugs within the same treatment class (i.e., other DPP‐4 inhibitors), and versus patients initiating drugs from other treatment classes (biguanides, sulfonylureas, thiazolidinediones \[TZDs\], alpha‐glucosidase inhibitors \[AGIs\] and glinides). Sodium--glucose co‐transporter‐2 inhibitors were also included, although these have only been available in Japan since 2014.

All statistical analyses were descriptive, and included the mean and standard deviation (SD), median and ranges, and absolute and relative frequencies. Absolute standardized differences (ASDs) for comparing linagliptin with other GLDs were calculated as the difference in mean (or proportion for binary variables) divided by the SD (pooled SD for continuous variables). An ASD \>10% was considered a meaningful difference[29](#jdi13012-bib-0029){ref-type="ref"}, [30](#jdi13012-bib-0030){ref-type="ref"}. All analyses were carried out using SAS version 9.4 (SAS Institute, Cary, NC, USA).

Results {#jdi13012-sec-0007}
=======

Patient disposition and baseline characteristics {#jdi13012-sec-0008}
------------------------------------------------

A total of 4,212 patients with type 2 diabetes mellitus were included in the study, of whom 2,164 (51%) were initiating linagliptin. Of the 2,048 patients beginning other GLDs, 1,325 (65%) were starting a DPP‐4 inhibitor other than linagliptin.

Baseline demographic and clinical characteristics are shown in Table [1](#jdi13012-tbl-0001){ref-type="table"}. Patients starting linagliptin were older compared with those initiating any other GLD (66.7 ± 12.5 vs 65.3 ± 12.5 years, respectively; ASD 10.8%), with lower HbA1c (7.4 ± 1.4% \[57 ± 15 mmol/mol\] vs 7.7 ± 1.6% \[61 ± 18 mmol/mol\], respectively; ASD 16.8%) and estimated glomerular filtration rate (eGFR; 70.8 ± 24.1 vs 76.4 ± 22.6 mL/min/1.73 m^2^, respectively; ASD 23.9%). Patients initiating linagliptin were of similar age to those starting other DPP‐4 inhibitors, but had lower HbA1c (7.4 ± 1.4% \[57 ± 15 mmol/mol\] vs 7.6 ± 1.5% \[60 ± 16 mmol/mol\], respectively; ASD 11.9%) and eGFR (70.8 ± 24.1 vs 75.4 ± 22.7 mL/min/1.73 m^2^, respectively; ASD 19.4%). Patients initiating linagliptin were older and had lower HbA1c and eGFR than those starting biguanides or sulfonylureas, but had higher HbA1c than patients beginning TZDs and AGIs, and higher eGFR compared with patients starting glinides (Table [1](#jdi13012-tbl-0001){ref-type="table"}).

###### 

Baseline characteristics of study participants: individuals treated with linagliptin versus all other glucose‐lowering drugs and specific glucose‐lowering drug classes

  Patient characteristic                                                   Linagliptin   Other GLDs[†](#jdi13012-note-0001){ref-type="fn"}   Other DPP‐4is   Biguanides    Sulfonylureas   TZDs          AGIs      Glinides                                                                     
  ------------------------------------------------------------------------ ------------- --------------------------------------------------- --------------- ------------- --------------- ------------- --------- ------------- ------ ------------- ------ ------------- ------ ------------- ------
  Patients (*n*)                                                           2,164         2,048                                               --              1,325         --              287           --        185           --     95            --     93            --     59            --
  Mean age, years (SD)                                                     66.7 (12.5)   65.3 (12.5)                                         10.8            66.4 (12.2)   1.9             59.2 (12.2)   60.3      64.6 (12.6)   16.4   67.3 (11.8)   5.5    66.9 (12.8)   1.7    67.1 (13.6)   3.2
  Male (%)                                                                 58.5          57.3                                                2.5             56.5          4.2             59.9          2.8       56.2          4.7    62.1          7.3    60.2          3.4    55.9          5.3
  Mean BMI, kg/m^2^ (SD)                                                   25.2 (4.2)    25.3 (4.3)                                          2.1             25.0 (4.1)    5.2             27.2 (4.6)    45.4      24.6 (3.8)    15.7   26.0 (5.3)    17.7   24.6 (3.9)    14.1   23.3 (3.4)    50.4
  Mean HbA1c, % (SD)                                                       7.4 (1.4)     7.7 (1.6)                                           16.8            7.6 (1.5)     11.9            7.9 (1.8)     28.7      8.7 (2.1)     73.8   6.9 (0.9)     43.7   7.0 (1.0)     35.0   7.4 (1.1)     0.7
  Mean HbA1c, mmol/mol (SD)                                                57 (15)       61 (18)                                             60 (16)         63 (20)       72 (23)         52 (10)       53 (11)   57 (12)                                                                      
  Mean eGFR, mL/min/1.73 m^2^ (SD)                                         70.8 (24.1)   76.4 (22.6)                                         23.9            75.4 (22.7)   19.4            82.9 (20.8)   53.5      82.1 (24.1)   46.6   70.7 (15.6)   0.5    71.7 (23.1)   3.8    68.4 (21.8)   10.5
  Hepatic dysfunction (%)[‡](#jdi13012-note-0001){ref-type="fn"}           7.9           9.3                                                 4.9             8.9           3.6             13.9          19.4      8.6           2.7    6.3           6.2    7.5           1.4    5.1           11.5
  Cardiovascular history, yes (%[)§](#jdi13012-note-0001){ref-type="fn"}   14.2          9.2                                                 15.6            9.8           13.6            6.3           26.5      8.1           19.5   13.7          1.6    7.5           21.7   10.2          12.4
  Duration of diabetes (%)                                                                                                                                                                                                                                                                      
  ≤1 year                                                                  22.3          21.8                                                1.3             21.4          2.1             26.5          9.7       16.8          14.1   22.1          0.5    24.7          5.7    18.6          9.1
  \>1--5 years                                                             20.7          19.5                                                2.9             20.2          1.1             20.2          1.1       17.3          8.6    17.9          7.0    17.2          8.8    13.6          18.9
  ≥5 years                                                                 17.0          16.8                                                0.4             16.0          2.7             16.7          0.7       24.3          18.1   20.0          7.7    12.9          11.5   13.6          9.6
  Unknown                                                                  40.0          41.9                                                --              42.3          --              36.6          --        41.6          --     40.0          --     45.2          --     54.2          --

^†^Includes biguanides, sulfonylureas, thiazolidinediones (TZDs), alpha‐glucosidase inhibitors (AGIs) and glinides. Four patients initiated glucose‐lowering drugs (GLDs) other than dipeptidyl peptidase‐4 inhibitors (DPP‐4is), biguanides, sulfonylureas, TZDs, AGIs or glinides. ^‡^Standardized Medical Dictionary for Regulatory Activities (MedDRA) queries 20000005 (hepatic disorders) and 20000118 (biliary disorders) -- narrow search terms. ^§^Standardized MedDRA queries 20000043 (ischemic heart disease), 20000004 (cardiac failure), 20000060 (cerebrovascular disorders) and 20000001 (torsade de pointes/QT prolongation) -- regardless of presence at baseline. ASD, absolute standardized difference versus linagliptin; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; SD, standard deviation.

John Wiley & Sons, Ltd

The proportion of patients in the different diabetes duration categories (≤1, 1--5, ≥5 years) was generally similarly distributed among the different GLDs, although more patients beginning sulfonylureas were in the ≥5 years category compared with patients initiating linagliptin (24.3 vs 17.0%, respectively; ASD 18.1%). Fewer patients starting AGIs were in the ≥5‐years category compared with patients initiating linagliptin (12.9 vs 17.0%, respectively; ASD 11.5%).

Pre‐existing comorbidities by SOC {#jdi13012-sec-0009}
---------------------------------

The proportions of patients with pre‐existing comorbidities by SOC are shown in Table [2](#jdi13012-tbl-0002){ref-type="table"}. Most SOC comorbidities were more common in patients initiating linagliptin compared with all other GLDs, with meaningful differences (linagliptin vs any other GLDs; ASD \>10%) observed for metabolism and nutritional disorders (50.5 vs 45.5%), cardiac disorders (12.2 vs 8.6%), vascular disorders (56.4 vs 51.3%), and renal and urinary disorders (9.9 vs 5.7%; Table [2](#jdi13012-tbl-0002){ref-type="table"}). Renal and urinary disorders were more common in patients initiating linagliptin versus patients starting any other DPP‐4 inhibitor (9.9 vs 5.1%; ASD 18.5%), although all other comorbidities were similarly frequent (Table [2](#jdi13012-tbl-0002){ref-type="table"}). Metabolism and nutritional disorders were more common (ASD \>10%) in patients beginning linagliptin (50.5%) than in patients initiating biguanides (44.6%), sulfonylureas (41.1%), TZDs (43.2%) and glinides (39.0%; Table [2](#jdi13012-tbl-0002){ref-type="table"}). Cardiac disorders were more frequent (ASD \>10%) in patients starting linagliptin (12.2%) than patients initiating biguanides (6.6%), sulfonylureas (5.9%) and AGIs (5.4%; Table [2](#jdi13012-tbl-0002){ref-type="table"}). Renal and urinary disorders were more common (ASD \>10%) among patients initiating linagliptin (9.9%) than patients starting biguanides (4.9%) and TZDs (4.2%; Table [2](#jdi13012-tbl-0002){ref-type="table"}). In contrast, hepatobiliary disorders were less frequent (ASD \>10%) among patients initiating linagliptin (7.3%) than those starting biguanides (13.9%; Table [2](#jdi13012-tbl-0002){ref-type="table"}).

###### 

Proportion of patients with pre‐existing comorbidities by system organ class: individuals treated with linagliptin compared with specific glucose‐lowering drug classes

  Disorder by SOC                                 Linagliptin (*n *= 2,164) % Of patients   Other GLDs[§](#jdi13012-note-0002){ref-type="fn"} (*n* = 2,048)   Other DPP‐4is (*n* = 1,325)                   Biguanides (*n* = 287)                       Sulfonylureas (*n* = 185)                     TZDs (*n* = 95)                               AGIs (*n* = 93)                               Glinides (*n* = 59)                                                                                                                                                                                                                                                                                                               
  ----------------------------------------------- ----------------------------------------- ----------------------------------------------------------------- --------------------------------------------- -------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------------
  Infections and infestations                     1.3                                       2.0                                                               4.8                                           2.3                                          7.4                                           0.7                                           6.4                                           2.7                                           9.7                                           1.1                                           2.6                                           1.1                                           2.4                                           0                                             16.5
  Neoplasms (benign, malignant and unspecified)   1.9                                       1.0                                                               7.7                                           0.9                                          8.4                                           1.0                                           7.1                                           0.5[†](#jdi13012-note-0002){ref-type="fn"}    12.4[†](#jdi13012-note-0002){ref-type="fn"}   1.1                                           7.0                                           3.2                                           8.4                                           0[†](#jdi13012-note-0002){ref-type="fn"}      19.7[†](#jdi13012-note-0002){ref-type="fn"}
  Blood and lymphatic system                      3.6                                       2.5                                                               6.5                                           2.6                                          6.0                                           2.4                                           6.8                                           2.2                                           8.6                                           1.1[†](#jdi13012-note-0002){ref-type="fn"}    17.0[†](#jdi13012-note-0002){ref-type="fn"}   3.2                                           2.1                                           3.4                                           1.2
  Endocrine                                       1.9                                       1.2                                                               5.4                                           1.2                                          5.6                                           0.3[†](#jdi13012-note-0002){ref-type="fn"}    14.7[†](#jdi13012-note-0002){ref-type="fn"}   0.5[†](#jdi13012-note-0002){ref-type="fn"}    12.4[†](#jdi13012-note-0002){ref-type="fn"}   2.1                                           1.5                                           1.1                                           6.8                                           6.8[‡](#jdi13012-note-0002){ref-type="fn"}    24.2[‡](#jdi13012-note-0002){ref-type="fn"}
  Metabolism and nutritional                      50.5                                      45.5[†](#jdi13012-note-0002){ref-type="fn"}                       10.0[†](#jdi13012-note-0002){ref-type="fn"}   46.6                                         7.7                                           44.6[†](#jdi13012-note-0002){ref-type="fn"}   11.9[†](#jdi13012-note-0002){ref-type="fn"}   41.1[†](#jdi13012-note-0002){ref-type="fn"}   19.0[†](#jdi13012-note-0002){ref-type="fn"}   43.2[†](#jdi13012-note-0002){ref-type="fn"}   14.8[†](#jdi13012-note-0002){ref-type="fn"}   49.5                                          2.1                                           39.0[†](#jdi13012-note-0002){ref-type="fn"}   23.3[†](#jdi13012-note-0002){ref-type="fn"}
  Psychiatric                                     5.7                                       5.2                                                               2.0                                           5.7                                          0.1                                           1.7[†](#jdi13012-note-0002){ref-type="fn"}    21.0[†](#jdi13012-note-0002){ref-type="fn"}   4.3                                           6.2                                           8.4[‡](#jdi13012-note-0002){ref-type="fn"}    10.7[‡](#jdi13012-note-0002){ref-type="fn"}   9.7[‡](#jdi13012-note-0002){ref-type="fn"}    15.0[‡](#jdi13012-note-0002){ref-type="fn"}   3.4[†](#jdi13012-note-0002){ref-type="fn"}    11.0[†](#jdi13012-note-0002){ref-type="fn"}
  Nervous system                                  9.2                                       7.1                                                               7.7                                           7.4                                          6.7                                           4.9[†](#jdi13012-note-0002){ref-type="fn"}    17.1[†](#jdi13012-note-0002){ref-type="fn"}   7.6                                           6.0                                           9.5                                           0.8                                           8.6                                           2.2                                           5.1[†](#jdi13012-note-0002){ref-type="fn"}    16.2[†](#jdi13012-note-0002){ref-type="fn"}
  Eye                                             1.8                                       1.3                                                               3.6                                           1.1                                          5.9                                           1.4                                           2.9                                           3.8[‡](#jdi13012-note-0002){ref-type="fn"}    12.4[‡](#jdi13012-note-0002){ref-type="fn"}   0[†](#jdi13012-note-0002){ref-type="fn"}      18.9[†](#jdi13012-note-0002){ref-type="fn"}   0[†](#jdi13012-note-0002){ref-type="fn"}      18.9[†](#jdi13012-note-0002){ref-type="fn"}   3.4[‡](#jdi13012-note-0002){ref-type="fn"}    10.3[‡](#jdi13012-note-0002){ref-type="fn"}
  Cardiac                                         12.2                                      8.6[†](#jdi13012-note-0002){ref-type="fn"}                        12.0[†](#jdi13012-note-0002){ref-type="fn"}   9.4                                          9.1                                           6.6[†](#jdi13012-note-0002){ref-type="fn"}    19.3[†](#jdi13012-note-0002){ref-type="fn"}   5.9[†](#jdi13012-note-0002){ref-type="fn"}    22.0[†](#jdi13012-note-0002){ref-type="fn"}   10.5                                          5.4                                           5.4[†](#jdi13012-note-0002){ref-type="fn"}    24.4[†](#jdi13012-note-0002){ref-type="fn"}   10.2                                          6.6
  Vascular                                        56.4                                      51.3[†](#jdi13012-note-0002){ref-type="fn"}                       10.3[†](#jdi13012-note-0002){ref-type="fn"}   53.5                                         5.9                                           46.7[†](#jdi13012-note-0002){ref-type="fn"}   19.6[†](#jdi13012-note-0002){ref-type="fn"}   44.9[†](#jdi13012-note-0002){ref-type="fn"}   23.3[†](#jdi13012-note-0002){ref-type="fn"}   48.4[†](#jdi13012-note-0002){ref-type="fn"}   16.1[†](#jdi13012-note-0002){ref-type="fn"}   48.4[†](#jdi13012-note-0002){ref-type="fn"}   16.1[†](#jdi13012-note-0002){ref-type="fn"}   54.2                                          4.4
  Respiratory, thoracic and mediastinal           4.9                                       4.7                                                               1.0                                           4.7                                          1.2                                           3.8                                           5.4                                           4.9                                           0.4                                           9.5[‡](#jdi13012-note-0002){ref-type="fn"}    17.6[‡](#jdi13012-note-0002){ref-type="fn"}   5.4                                           2.0                                           1.7[†](#jdi13012-note-0002){ref-type="fn"}    18.2[†](#jdi13012-note-0002){ref-type="fn"}
  Gastrointestinal                                12.1                                      9.8                                                               7.4                                           10.3                                         5.7                                           5.6[†](#jdi13012-note-0002){ref-type="fn"}    23.0[†](#jdi13012-note-0002){ref-type="fn"}   7.6[†](#jdi13012-note-0002){ref-type="fn"}    15.1[†](#jdi13012-note-0002){ref-type="fn"}   8.4[†](#jdi13012-note-0002){ref-type="fn"}    12.0[†](#jdi13012-note-0002){ref-type="fn"}   22.6[‡](#jdi13012-note-0002){ref-type="fn"}   28.1[‡](#jdi13012-note-0002){ref-type="fn"}   8.5[†](#jdi13012-note-0002){ref-type="fn"}    11.8[†](#jdi13012-note-0002){ref-type="fn"}
  Hepatobiliary                                   7.3                                       8.5                                                               4.8                                           7.9                                          2.5                                           13.9[‡](#jdi13012-note-0002){ref-type="fn"}   21.8[‡](#jdi13012-note-0002){ref-type="fn"}   8.1                                           3.2                                           6.3                                           3.7                                           6.5                                           3.2                                           5.1                                           9.0
  Skin and subcutaneous tissue                    1.1                                       0.9                                                               1.4                                           0.8                                          3.2                                           1.7                                           5.8                                           1.1                                           0.2                                           0[†](#jdi13012-note-0002){ref-type="fn"}      14.7[†](#jdi13012-note-0002){ref-type="fn"}   1.1                                           0.1                                           1.7                                           5.4
  Musculoskeletal and connective tissue           6.0                                       5.7                                                               1.1                                           6.6                                          2.5                                           2.4[†](#jdi13012-note-0002){ref-type="fn"}    17.6[†](#jdi13012-note-0002){ref-type="fn"}   4.9                                           4.8                                           3.2[†](#jdi13012-note-0002){ref-type="fn"}    13.5[†](#jdi13012-note-0002){ref-type="fn"}   6.5                                           2.0                                           8.5                                           9.7
  Renal and urinary                               9.9                                       5.7[†](#jdi13012-note-0002){ref-type="fn"}                        15.8[†](#jdi13012-note-0002){ref-type="fn"}   5.1[†](#jdi13012-note-0002){ref-type="fn"}   18.5[†](#jdi13012-note-0002){ref-type="fn"}   4.9[†](#jdi13012-note-0002){ref-type="fn"}    19.3[†](#jdi13012-note-0002){ref-type="fn"}   7.6                                           8.2                                           4.2[†](#jdi13012-note-0002){ref-type="fn"}    22.3[†](#jdi13012-note-0002){ref-type="fn"}   10.8                                          2.8                                           11.9                                          6.3
  Reproductive system and breast                  2.2                                       1.6                                                               4.8                                           1.7                                          3.5                                           1.0                                           9.3                                           0.5[†](#jdi13012-note-0002){ref-type="fn"}    14.4[†](#jdi13012-note-0002){ref-type="fn"}   2.1                                           0.8                                           3.2                                           6.2                                           0[†](#jdi13012-note-0002){ref-type="fn"}      21.3[†](#jdi13012-note-0002){ref-type="fn"}

Meaningful differences for comorbidities that are more common with linagliptin versus comparator glucose‐lowering drug (GLD); ^‡^meaningful differences for comorbidities that are more common with the comparator GLD versus linagliptin. All system organ classes (SOCs) with ≥1% of patients starting treatment with either linagliptin or "all other GLDs" affected are shown. ^§^Includes biguanides, sulfonylureas, thiazolidinediones (TZDs), alpha‐glucosidase inhibitors (AGIs) and glinides. Four patients initiated GLDs other than dipeptidyl peptidase‐4 inhibitors (DPP‐4is), biguanides, sulfonylureas, TZDs, AGIs or glinides. ASD, absolute standardized difference.
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Pre‐existing comorbidities by preferred term {#jdi13012-sec-0010}
--------------------------------------------

With the exception of arrhythmia, all preferred term comorbidities were more common with linagliptin compared with all other GLDs, with meaningful differences (ASD \>10%) observed for angina pectoris (5.0 vs 3.0%, respectively) and CKD (4.4 vs 2.1%, respectively), as well as compared with other DPP‐4 inhibitors, with meaningful differences in angina pectoris (5.0 vs 3.0%, respectively), CKD (4.4 vs 2.3%, respectively) and diabetic nephropathy (2.7 vs 1.0%, respectively; Table [S1](#jdi13012-sup-0001){ref-type="supplementary-material"}).

Discussion {#jdi13012-sec-0011}
==========

The collection of baseline characteristic data from patients initiating treatment other than linagliptin represents a novel approach for a standard required Japanese PMS study. The expansion of the linagliptin Japan PMS study to include collection of baseline characteristics in patients who were eligible for linagliptin treatment, but initiating GLDs other than linagliptin, showed the spectrum of patients receiving linagliptin, and enabled the identification of preferential prescribing of linagliptin in patients with cardiac, vascular, renal/urinary and metabolism/nutritional disorders. Although preferential prescribing could be anticipated based on pharmacokinetic data (indicating that dose adjustment is not required) and clinical trial data reflected in the prescribing information (showing safety and efficacy in these patients[8](#jdi13012-bib-0008){ref-type="ref"}, [9](#jdi13012-bib-0009){ref-type="ref"}, [10](#jdi13012-bib-0010){ref-type="ref"}, [11](#jdi13012-bib-0011){ref-type="ref"}, [12](#jdi13012-bib-0012){ref-type="ref"}, [13](#jdi13012-bib-0013){ref-type="ref"}, [14](#jdi13012-bib-0014){ref-type="ref"}, [15](#jdi13012-bib-0015){ref-type="ref"}, [16](#jdi13012-bib-0016){ref-type="ref"}, [17](#jdi13012-bib-0017){ref-type="ref"}, [18](#jdi13012-bib-0018){ref-type="ref"}), this phenomenon can only be determined in a real‐world data study with comparator data.

DPP‐4 inhibitors are well established in clinical practice in Japan[4](#jdi13012-bib-0004){ref-type="ref"}, [5](#jdi13012-bib-0005){ref-type="ref"}, as reflected by 65% of patients among those who did not start linagliptin, but initiated another DPP‐4 inhibitor. In contrast with treatment guidelines in the USA and Europe[31](#jdi13012-bib-0031){ref-type="ref"}, [32](#jdi13012-bib-0032){ref-type="ref"}, the Japanese Diabetes Society Treatment Guide for Diabetes during the study and at the present time does not give precedence to first‐line treatment with biguanides, such as metformin, over other GLDs[3](#jdi13012-bib-0003){ref-type="ref"}. In terms of patient age, body mass index, HbA1c, eGFR and cardiovascular disease history, the patients who received linagliptin in the present study were comparable with the wider Japanese type 2 diabetes mellitus patient population described by Yokoyama *et al*.[26](#jdi13012-bib-0026){ref-type="ref"}

Although the data reported here are most relevant to Japan (given the distinct patient population, health system and diabetes treatment paradigm compared with other countries), similar "channeling" has been observed for linagliptin in the USA population[19](#jdi13012-bib-0019){ref-type="ref"}. In that study, the prevalence of baseline kidney disease (overall kidney dysfunction, any stage of CKD, respectively) was higher among patients initiating linagliptin (22.4%, 12.9%), glinides (28.7%, 16.7%) or insulin (27.0%, 13.5%) compared with other DPP‐4 inhibitors (16.7%, 8.6%), sulfonylureas (second generation; 16.9%, 8.5%), glitazones (18.6%, 10.1%), glucagon‐like peptide‐1 receptor agonists (13.4%, 6.1%), sodium--glucose co‐transporter‐2 inhibitors (10.3%, 4.1%) or metformin (9.4%, 3.9%)[19](#jdi13012-bib-0019){ref-type="ref"}. Similar observations have also been noted for other GLDs in the USA population[33](#jdi13012-bib-0033){ref-type="ref"}, [34](#jdi13012-bib-0034){ref-type="ref"}, [35](#jdi13012-bib-0035){ref-type="ref"}, [36](#jdi13012-bib-0036){ref-type="ref"}.

The novel approach of expanding a standard, required PMS to collect baseline data from patients initiating other medications for the same indication shows the importance and potential impact if data on a newly marketed product are considered in isolation. In the absence of comparator data, the presence and extent of preferential prescribing cannot be assessed. Consequently, in the setting of a standard single‐arm PMS program, interpretation of safety and effectiveness data of a new medication might be difficult. Expansion of such studies to include at least the collection of baseline characteristics of patients initiating other medications for the same indication could be a critical step in the identification and quantification of preferential prescribing, and in strengthening the interpretability of the safety and effectiveness of newly marketed medications, which is key for public health.

The strengths of these data from the expanded linagliptin PMS study include the large number of patients overall, the real‐world, routine clinical practice setting and minimal exclusion criteria. The setting did, however, result in a small imbalance in the number of patients initiating linagliptin compared with other GLDs, as it was not always possible to follow recruitment of a patient initiating linagliptin with a patient initiating any other GLD. The study was limited by the small patient numbers for individual drug classes other than DPP‐4 inhibitors; however, this reflects treatment patterns in Japan at the time of the study. In addition, we did not collect specific information on the category of physician. The ratio of hospital : primary care physicians was 1:7. Therefore, the vast majority of prescribing physicians in the PMS were in primary care. It would be reasonable to assume that most of the hospital‐based physicians were specialists; however, we do not have the data to support this notion. Furthermore, although no study medication was provided and treatment decisions were solely at the discretion of the physician and patient, it could be argued that participation in the study might have altered physician and/or patient behavior. While this is a limitation, the results from the present study are consistent with other findings from studies using existing data[19](#jdi13012-bib-0019){ref-type="ref"}, suggesting that any study participation bias in the current study was minimal.

In conclusion, the novel approach of expanding the linagliptin PMS enabled detection of linagliptin prescribing to a type 2 diabetes mellitus patient population with more comorbidities, specifically renal, vascular, cardiac, and metabolism and nutritional disorders, compared with patients prescribed other GLDs. Such preferential prescribing needs to be accounted for when comparing safety and effectiveness data for linagliptin with those of other GLDs in a non‐randomized study to avoid biased comparisons and erroneous conclusions. Thus, the findings from the present study generate insights that are important for the design and interpretation of observational studies and spontaneous reports.
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**Table S1** ¦ Proportion of patients with pre‐existing comorbidities by preferred term: individuals treated with linagliptin compared with specific glucose‐lowering drug classes.
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